GET DAILY SIGNALSWhy Is Arcturus Therapeutics (ARCT) Stock Down -8.98% Today?
Key Takeaways
- ARCT shares fell 8.98% to $10.04 in Monday's session, down from Friday's close of $11.03.
- The decline extends last week's pullback, with no single company-specific headline driving the move.
- Profit-taking and pre-earnings de-risking ahead of the company's third-quarter report on November 5 are weighing on the stock.
- The shares' high beta and elevated short interest are amplifying downside momentum after a strong multi-month rally.
- Investors are watching the upcoming Q3 results and any updates on the cystic fibrosis and OTC deficiency pipeline programs.
- For deeper insight, explore Price Targets, Earnings, and Forecast pages for ARCT.
- Discover AI-powered trading strategies currently in favor by visiting Trending AI Robots.
Opening Summary
Arcturus Therapeutics Holdings Inc. (ARCT), a San Diego-based messenger RNA (mRNA) medicines company developing treatments for rare liver and respiratory diseases, extended its recent slide on Monday, trading down 8.98% to $10.04. The move follows a prior-session close of $11.03 and builds on a steep decline seen late last week. With no major company-specific announcement triggering the move, markets attributed the selling to a combination of profit-taking after a powerful rally and caution ahead of the company's upcoming earnings report.
Profit-Taking After a Strong Rally
The decline reflects a natural unwind of a sharp run-up. ARCT shares surged roughly 90% over the trailing three-month period, propelled by positive interim Phase 2 data for ARCT-810 in ornithine transcarbamylase (OTC) deficiency, the introduction of its next-generation LUNAR 2.0 delivery platform, a Citi upgrade to Buy, and the strategic acquisition of myNEO. After reaching a 52-week high near $18, momentum stalled, and traders have been locking in gains. High-momentum biotechnology names are particularly vulnerable to rapid reversals once upward catalysts are digested, and the stock's slide below its 50-day moving average has added technical selling pressure.
Positioning Ahead of Third-Quarter Earnings
The company is scheduled to report third-quarter financial results and provide a corporate update on November 5. Ahead of the print, investors often trim exposure to high-beta, unprofitable biotechs to reduce event risk. Arcturus' revenue has contracted sharply following the termination of its collaboration with CSL Seqirus, with second-quarter revenue falling roughly 89% year over year as the partnership wound down. With the market expecting continued losses, some holders are de-risking into the report rather than carrying elevated volatility through the announcement.
High Beta and Elevated Short Interest Amplify Moves
ARCT carries a beta near 2.5, meaning it tends to move roughly two-and-a-half times the broader market, and roughly 19% of its shares outstanding are sold short. These characteristics magnify downside moves during periods of profit-taking, as selling begets further selling. The stock's retreat below key technical levels, including its 50-day moving average near $13.60, has reinforced the bearish near-term tape even as the shares remain above their 200-day moving average.
Market Context and Trading Activity
Trading volume has been elevated relative to the stock's recent average, consistent with heightened activity among momentum and speculative names. The move diverges from the broader tape, indicating company- and sector-specific dynamics rather than a market-wide event. Risk appetite within small- and mid-cap biotechnology has been uneven, with investors rotating away from extended, catalyst-dependent names toward more defensive positioning. The pullback underscores how quickly sentiment can shift in the clinical-stage biotech segment, where valuations hinge on future data readouts rather than current earnings.
What Comes Next for ARCT
The primary near-term catalyst is the November 5 earnings release and corporate update, where investors will look for commentary on cash runway, collaboration revenue, and pipeline milestones. Key developments include the expected decision on advancing ARCT-032 into Phase 3 in cystic fibrosis during the fourth quarter, as well as further clarity on the OTC deficiency program and the recently regained KOSTAIVE vaccine portfolio. Risks include continued revenue contraction, ongoing net losses, and the inherent uncertainty of clinical-stage development. Broader biotech sentiment and any shifts in risk appetite will also influence trading in the sessions ahead.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots that are performing most strongly under current market conditions. Tickeron offers hundreds of automated trading bots covering thousands of tickers, with each bot varying by strategy, timeframe, performance metrics, and the symbols it trades. Explore the page to see which strategies are gaining traction in today's market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for ARCT turns positive, indicating new upward trend
ARCT saw its Momentum Indicator move above the 0 level on October 28, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned positive. In 72 of the 86 cases, the stock moved higher in the following days. The odds of a move higher are at 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ARCT just turned positive on October 29, 2026. Looking at past instances where ARCT's MACD turned positive, the stock continued to rise in 41 of 49 cases over the following month. The odds of a continued upward trend are 84%.
Following a +8.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARCT advanced for three days, in 229 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
ARCT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
ARCT moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ARCT crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ARCT entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.825) is normal, around the industry mean (3.162). P/E Ratio (-3.312) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (23.364) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. ARCT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of technology and therapeutics for rare diseases
Industry Biotechnology
Advertisement